Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H16N8O |
Molecular Weight | 372.3833 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OCCN1C=C(C=N1)C2=CN=C3N=NN(CC4=CC=C5N=CC=CC5=C4)C3=N2
InChI
InChIKey=PDMUGYOXRHVNMO-UHFFFAOYSA-N
InChI=1S/C19H16N8O/c28-7-6-26-12-15(9-22-26)17-10-21-18-19(23-17)27(25-24-18)11-13-3-4-16-14(8-13)2-1-5-20-16/h1-5,8-10,12,28H,6-7,11H2
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/19459657 | https://www.ncbi.nlm.nih.gov/pubmed/26013381Curator's Comment: Description was created based on several sources, including http://adisinsight.springer.com/drugs/800027901
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19459657 | https://www.ncbi.nlm.nih.gov/pubmed/26013381
Curator's Comment: Description was created based on several sources, including http://adisinsight.springer.com/drugs/800027901
PF-04217903 is a triazolopyrazine inhibitor of c-MET that displays anticancer chemotherapeutic and anti-metastatic activities. PF-04217903 inhibits cell proliferation, invasion, and migration as well as tumor growth in various cancer models. In animal models of pancreatic neuroendocrine tumors, this compound prevents lymph node metastasis. PF-04217903 had been in phase I clinical trials by Pfizer for the treatment of solid tumors. In 2011, the company discontinued the development of the compound.
Originator
Sources: http://adisinsight.springer.com/drugs/800027901
Curator's Comment: # Pfizer
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3717 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19459657 |
4.8 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.24 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21098644 |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
PF-04217903 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.81 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21098644 |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
PF-04217903 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
6.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21098644 |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
PF-04217903 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
16.4% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21098644 |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
PF-04217903 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00706355
Escalating doses of PF-04217903 will be administered orally on a continuous dosing schedule. Doses to be evaluated will range from 50 mg BID to 1000 mg BID. A cycle is considered to be 21 days
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26013381
Treatment with 100 nM of PF-04217903 for 4 hours resulted in decreased p-MET, pERK, p-AKT and p-PLCγ1 in mouse melanocytes expressing TRIM4-MET or ZKSCAN1-MET
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C143099
Created by
admin on Sat Dec 16 01:37:56 GMT 2023 , Edited by admin on Sat Dec 16 01:37:56 GMT 2023
|
||
|
NCI_THESAURUS |
C129825
Created by
admin on Sat Dec 16 01:37:56 GMT 2023 , Edited by admin on Sat Dec 16 01:37:56 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
956905-27-4
Created by
admin on Sat Dec 16 01:37:56 GMT 2023 , Edited by admin on Sat Dec 16 01:37:56 GMT 2023
|
PRIMARY | |||
|
17754438
Created by
admin on Sat Dec 16 01:37:56 GMT 2023 , Edited by admin on Sat Dec 16 01:37:56 GMT 2023
|
PRIMARY | |||
|
DB12848
Created by
admin on Sat Dec 16 01:37:56 GMT 2023 , Edited by admin on Sat Dec 16 01:37:56 GMT 2023
|
PRIMARY | |||
|
CYJ9ATV1IJ
Created by
admin on Sat Dec 16 01:37:56 GMT 2023 , Edited by admin on Sat Dec 16 01:37:56 GMT 2023
|
PRIMARY | |||
|
DTXSID401026097
Created by
admin on Sat Dec 16 01:37:56 GMT 2023 , Edited by admin on Sat Dec 16 01:37:56 GMT 2023
|
PRIMARY | |||
|
300000041325
Created by
admin on Sat Dec 16 01:37:56 GMT 2023 , Edited by admin on Sat Dec 16 01:37:56 GMT 2023
|
PRIMARY | |||
|
CHEMBL2001019
Created by
admin on Sat Dec 16 01:37:56 GMT 2023 , Edited by admin on Sat Dec 16 01:37:56 GMT 2023
|
PRIMARY | |||
|
C78483
Created by
admin on Sat Dec 16 01:37:56 GMT 2023 , Edited by admin on Sat Dec 16 01:37:56 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)